Laura Litwin

Lung Cancers Today

<p>On July 2, 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical Co, Ltd) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations in adults, according to an announcement.</p>
<p>The organization previously granted priority review and breakthrough therapy designation to the application for the drug.</p>
<p>Simultaneously, the FDA also approved the Oncomine Dx Express Test (Life Technologies Corporation) as a “companion diagnostic device to aid in detecting EGFR exon 20 insertion mutations in patients with NSCLC who may be eligible for treatment with Zegfrovy.”</p>
<p>The FDA announcement highlighted that WU-KONG1B, a multinational, open-label, dose randomization trial evaluated the efficacy of the drug in 85 patients who were diagnosed with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who experienced disease progression on or after platinum-based chemotherapy.</p>
<p>Eligible participants received 200 mg orally of sunvozertinib once daily with food “until disease progression or intolerable toxicity.”</p>
<p>Overall response rate (ORR) was listed as the main efficacy outcome and duration of response (DOR) was listed as an additional efficacy outcome. ORR was confirmed via RECIST v1.1 through an assessment by a blinded independent review committee. The study ORR was 46% (95% CI: 35, 57) and the DOR was 11.1 months (95% CI: 8.2, not evaluable).</p>
<p>Furthermore, FDA officials emphasized that prescribers should be aware of the medication’s warnings and precautions, which include interstitial lung disease or pneumonitis, gastrointestinal adverse reactions, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity.</p>
<p>“The recommended sunvozertinib dose is 200 mg orally once daily with food until disease progression or unacceptable toxicity,” officials explained in the announcement.</p>
<div class="post-references"><h3>References</h3><p>U.S. Food &amp; Drug Administration. Accessed July 3, 2025. <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20</a>.</p>
</div>

<p>On July 2, 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical Co, Ltd) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations in adults, according to an announcement.</p><p>The organization previously granted priority review and breakthrough therapy designation to the application for the drug.</p><p>Simultaneously, the FDA also approved the Oncomine Dx Express Test (Life Technologies Corporation) as a “companion diagnostic device to aid in detecting EGFR exon 20 insertion mutations in patients with NSCLC who may be eligible for treatment with Zegfrovy.”</p><p>The FDA announcement highlighted that WU-KONG1B, a multinational, open-label, dose randomization trial evaluated the efficacy of the drug in 85 patients who were diagnosed with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who experienced disease progression on or after platinum-based chemotherapy.</p><p>Eligible participants received 200 mg orally of sunvozertinib once daily with food “until disease progression or intolerable toxicity.”</p><p>Overall response rate (ORR) was listed as the main efficacy outcome and duration of response (DOR) was listed as an additional efficacy outcome. ORR was confirmed via RECIST v1.1 through an assessment by a blinded independent review committee. The study ORR was 46% (95% CI: 35, 57) and the DOR was 11.1 months (95% CI: 8.2, not evaluable).</p><p>Furthermore, FDA officials emphasized that prescribers should be aware of the medication’s warnings and precautions, which include interstitial lung disease or pneumonitis, gastrointestinal adverse reactions, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity.</p><p>“The recommended sunvozertinib dose is 200 mg orally once daily with food until disease progression or unacceptable toxicity,” officials explained in the announcement.</p><div class="post-references"><h3>References</h3><p>U.S. Food &amp; Drug Administration. Accessed July 3, 2025. <a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sunvozertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20</a>.</p>
</div>

FDA Grants Accelerated Approval of Sunvozertinib for Metastatic EGFR-Positive NSCLC

EGFR+ NSCLC

Lung Cancers Today Editors

AGEAN: Analysis Explores Impact of Post-Surgical MRD Status in NSCLC

Conference Coverage

Study Investigates Targeted Interventions to Improve Lung Cancer Screening Uptake in High-Risk Patients

Non-Sponsored

HERTHENA-Lung02 Evaluates Patritumab Deruxtecan in EGFR-Mutated NSCLC

ASCO 2025

DART Trial Assesses Relationship Between ctDNA and Outcomes in Unresectable NSCLC

Non-Small Cell Lung Cancer

Alexi Archambault, PhD, MPH

ASCO 2025: Dr. Alexi Archambault Discusses the First-Line Combination of Cemiplimab and Chemotherapy for NSCLC

Latest News

The organization previously granted priority review and breakthrough therapy designation to the application for the drug.

Sunvozertinib Granted Accelerated FDA Approval for Metastatic EGFR-Positive NSCLC